Genexine ranked among the top searched stocks for 12 days in the past month.


As of 9:30 AM on the 8th, Genexine is trading at 172,700 KRW, down 1.65% from the previous day. This represents a 46.36% increase compared to August 12. Genexine is known as a company specializing in the development of biopharmaceuticals.

Over the past five days, individual investors have sold a net 30,858 shares, while foreigners and institutions have bought a net 130,959 shares and sold a net 95,730 shares, respectively.


On August 31, Genexine became a market issue with the news of "FDA approval for Kimria combination therapy Phase 1b clinical trial," leading to a price increase.



※Source: AI Investment Assistant AI Lassiro


※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing